Animal Models for Human Risk Assessment: The Peroxisome Proliferator-Activated Receptor Alpha-Humanized Mouse

Nutrition Reviews

Volumn 65, Issue SUPPL.1, 2007, Pages

  Gonzalez, Frank J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Hepatocarcinogenesis; Hyperlipidemic fibrate drugs; Nuclear receptors; Peroxisome proliferator activated receptor alpha; PPAR

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ANIMAL; DISEASE MODEL; HUMAN; LIVER TUMOR; METABOLISM; METHODOLOGY; MOUSE; PATHOLOGY; REVIEW; RISK ASSESSMENT; SPECIES DIFFERENCE;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; LIVER NEOPLASMS; MICE; PPAR ALPHA; RISK ASSESSMENT; SPECIES SPECIFICITY;

EID: 34547412077     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/j.1753-4887.2007.tb00323.x     Document Type: Article

References (17)

1. Gronemeyer H., Gustafsson JA, Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 2004;3:S950-S964.
2. Desvergne B., Michalik L., Wahli W. Be fit or be sick: peroxisome proliferator-activated receptors are down the road. Mol Endocrinol 2004;8:S1321-S1332.
3. Nahle Z. PPAR trilogy from metabolism to cancer. Curr Opin Clin Nutr Metab Care 2004;7:S397-S402.
4. Issemann I., Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990;347:S645-S650.
5. Lee SS, Pineau T., Drago J., et al. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 1995;15:S3012-S3022.
6. Kersten S., Seydoux J., Peters JM, et al. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 1999;103:S1489-S1498.
7. Berger J., Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002;53:S409-S435.
8. Reddy JK, Azarnoff DL, Svoboda DJ, Prasad JD. Nafenopin-induced hepatic microbody (peroxisome) proliferation and catalase synthesis in rats and mice. Absence of sex difference in response. J Cell Biol 1974;61:S344-S358.
9. Reddy JK, Azarnoff DL, Hignite CE. Hypolipidaemichepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature 1980;283:S397-S398.
10. Peters JM, Cattley RC, Gonzalez FJ. Role of PPAR alpha in the mechanism of action of the nongeno-toxic carcinogen and peroxisome proliferator Wy-14, 643. Carcinogenesis 1997;18:S2029-S2033.
11. Gonzalez FJ, Peters JM, Cattley RC. Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor alpha. J Natl Cancer Inst 1998;90:S1702-S1709.
12. Palmer CN, Hsu MH, Griffin KJ, Ravey JL, Johnson EF. Peroxisome proliferator activated receptor-alpha expression in human liver. Mol Pharmacol 1998;53:S14-S22.
13. Peraza MA, Burdick AD, Marin HE, Gonzalez FJ, Peters JM. The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). Toxicol Sci 2006;90:S269-S295.
14. Brown PJ, Winegar DA, Plunket KD, et al. A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity. J Med Chem. 1999;42:S3785-S3788.
15. Berger JP, Akiyama TE, Meinke PT. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 2005;26:S244-S251.
16. Cheung C., Akiyama TE, Ward JM, et al. Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor alpha. Cancer Res 2004;64:S3849-S3854.
17. Morimura K., Cheung C., Ward JM, Reddy K., Gonzalez FJ. Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor alpha to Wy-14, 643-induced liver tumorigenesis. Carcinogenesis 2006;27:S1074-S1080.